Chronic yeast infection can cause other systemic problems other than recurrent vaginal infections. Often, this is due to body PH and antibiotic usage which will change the body PH can make you susceptible. People who have diabetes or use oral contraceptives may also be at risk for candidiasis (candida Albicans infection).
The FDA has just approved the first antifungal directed at chronic yeast infections.
Vivjoa (oteseconazole capsules), is meant for people with internal genitals, who have a history of recurrent vulvovaginal candidiasis (RVVC)—which equates to having three or more yeast infections within a 12-month period. The drug is only for post-menopausal women or for those who are infertile, as animal studies showed it may damage a fetus.
Read more below
The antifungal is intended for use in postmenopausal or infertile women with a history of recurrent infections.
By Julia Ries Published on May 10, 2022
For some people who experience chronic yeast infections, relief may be in sight: The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind antifungal medication to treat the recurrent condition.
The drug, Vivjoa (oteseconazole capsules), is meant for people with internal genitals, who have a history of recurrent vulvovaginal candidiasis (RVVC)—that equates to having three or more yeast infections within a 12-month period. Only people who are postmenopausal or infertile are approved to use Vivjoa; animal studies suggest the drug may cause fetal harm, so people who are pregnant, breastfeeding, or may become pregnant should not take it.
Still, the new treatment option—the first one in nearly 20 years—is a welcomed addition among patients and prescribers alike.